Search Results for "Pregnancy"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Pregnancy. Results 381 to 390 of 981 total matches.

Drugs for Epilepsy

   
The Medical Letter on Drugs and Therapeutics • Aug 05, 2024  (Issue 1708)
and Pregnancy – The potential risk to offspring from in utero exposure to ASMs is generally considered ...
When used for the appropriate seizure type, antiseizure medications (ASMs) are roughly equivalent in efficacy. In addition to the seizure type, the choice of drug is usually based on factors such as ease of use, spectrum of activity, adverse effects, interactions with other drugs, presence of comorbid conditions, suitability for elderly persons and those with childbearing potential, and cost. Treatment should begin with a single drug, increasing the dosage gradually until seizures are controlled or adverse effects become unacceptable. If seizures persist, expert clinicians generally...
Med Lett Drugs Ther. 2024 Aug 5;66(1708):121-8   doi:10.58347/tml.2024.1708a |  Show IntroductionHide Introduction

Pneumococcal Vaccine

   
The Medical Letter on Drugs and Therapeutics • Sep 10, 1999  (Issue 1061)
treatment. It can be given at the same time as influenza vaccine, at a different site. Use during pregnancy ...
Increased resistance of pneumococci to antimicrobial drugs may encourage more extensive use of pneumococcal polysaccharide vaccine.
Med Lett Drugs Ther. 1999 Sep 10;41(1061):84 |  Show IntroductionHide Introduction

In Brief: Retifanlimab (Zynyz) for Merkel Cell Carcinoma (online only)

   
The Medical Letter on Drugs and Therapeutics • Apr 17, 2023  (Issue 1674)
) before or after being treated with a PD-1/PD-L1 blocking antibody. PREGNANCY AND LACTATION — Inhibition ...
Retifanlimab-dlwr (Zynyz – Incyte), a programmed death receptor-1 (PD-1) blocking antibody, has received accelerated approval from the FDA for treatment of metastatic or recurrent locally advanced Merkel cell carcinoma (MCC) in adults. Accelerated approval of the drug was based on the response rate and duration of response. Retifanlimab is the third drug to be approved in the US for treatment of MCC; pembrolizumab (Keytruda), a PD-1 blocking antibody, is approved for the same indication as retifanlimab in patients ≥12 years old and avelumab (Bavencio), a programmed death...
Med Lett Drugs Ther. 2023 Apr 17;65(1674):e73-4   doi:10.58347/tml.2023.1674h |  Show IntroductionHide Introduction

Inavolisib (Itovebi) for Locally Advanced or Metastatic Breast Cancer (online only)

   
The Medical Letter on Drugs and Therapeutics • Nov 11, 2024  (Issue 1715)
, nausea, decreased appetite, diarrhea, and hematologic toxicity. PREGNANCY AND LACTATION – Inavolisib ...
Inavolisib (Itovebi – Genentech), an oral kinase inhibitor, has been approved by the FDA for use in combination with palbociclib and fulvestrant for treatment of endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer. This is the first approval for Itovebi; palbociclib and fulvestrant have been available for years for treatment of HR-positive, HER2-negative breast cancer.
Med Lett Drugs Ther. 2024 Nov 11;66(1715):e186-7   doi:10.58347/tml.2024.1715f |  Show IntroductionHide Introduction

Three New Oral Contraceptives

   
The Medical Letter on Drugs and Therapeutics • Sep 25, 2006  (Issue 1244)
symptoms, particularly withdrawal bleeding, and decrease the risk of ovulation and pregnancy. One study ...
Three new combination oral contraceptives (COCs) with shortened hormone-free intervals, Seasonique, Loestrin 24 Fe and Yaz, have recently been approved by the FDA. All 3 are derivatives of older products.
Med Lett Drugs Ther. 2006 Sep 25;48(1244):77-8 |  Show IntroductionHide Introduction

Ciclesonide (Omnaris) for Allergic Rhinitis

   
The Medical Letter on Drugs and Therapeutics • May 05, 2008  (Issue 1285)
not affect growth velocity. 4 PREGNANCY — Ciclesonide is rated category C (risk cannot be ruled out ...
Ciclesonide (Omnaris - Sepracor/Nycomed), a once daily corticosteroid nasal spray, is now available for treatment of seasonal allergic rhinitis (SAR) in adults and children ≥6 years old and for perennial allergic rhinitis (PAR) in those ≥12 years old. An orally inhaled formulation of ciclesonide (Alvesco) was recently approved by the FDA for maintenance treatment of asthma, and will be reviewed in a future issue of The Medical Letter
Med Lett Drugs Ther. 2008 May 5;50(1285):33-4 |  Show IntroductionHide Introduction

Oritavancin (Orbactiv) for Skin and Skin Structure Infections

   
The Medical Letter on Drugs and Therapeutics • Jan 05, 2015  (Issue 1459)
of oritavancin and dalbavancin appear to be similar. PREGNANCY – Oritavancin is classified as category C ...
The FDA has approved oritavancin (Orbactiv – The Medicines Company), a long-acting lipoglycopeptide antibiotic given as a single intravenous (IV) dose, for treatment of acute bacterial skin and skin structure infections caused by susceptible gram-positive bacteria in adults. It is the third lipoglycopeptide antibiotic to be marketed in the US; telavancin (Vibativ) and dalbavancin (Dalvance) were approved earlier.
Med Lett Drugs Ther. 2015 Jan 5;57(1459):3-5 |  Show IntroductionHide Introduction

Olodaterol (Striverdi Respimat) for COPD

   
The Medical Letter on Drugs and Therapeutics • Jan 05, 2015  (Issue 1459)
; there is no evidence to date that patients with COPD are at risk. PREGNANCY — Olodaterol is classified as category C ...
Olodaterol (Striverdi Respimat – Boehringer Ingelheim), a new inhaled long-acting beta2-agonist, has been approved by the FDA for once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD). It is not approved for treatment of acute exacerbations of COPD or for treatment of asthma. Olodaterol is the third long-acting beta2-agonist to be approved by the FDA for once-daily use; indacaterol (Arcapta Neohaler), which is available as a single agent, and vilanterol, which is available only in fixed-dose combinations with the...
Med Lett Drugs Ther. 2015 Jan 5;57(1459):1-3 |  Show IntroductionHide Introduction

Tiotropium/Olodaterol (Stiolto Respimat) for COPD

   
The Medical Letter on Drugs and Therapeutics • Nov 23, 2015  (Issue 1482)
risk of death compared to placebo.10 PREGNANCY — Stiolto Respimat is classified as category C (fetal ...
The FDA has approved a fixed-dose, orally inhaled combination of the long-acting anticholinergic tiotropium and the long-acting beta2-adrenergic agonist olodaterol (Stiolto Respimat — Boehringer Ingelheim) for long-term, once-daily, maintenance treatment of airflow obstruction in chronic obstructive pulmonary disease (COPD). It is not approved for treatment of acute exacerbations of COPD or for treatment of asthma. Tiotropium (Spiriva Handihaler, Spiriva Respimat) and olodaterol (Striverdi Respimat) are also available separately for once-daily treatment of...
Med Lett Drugs Ther. 2015 Nov 23;57(1482):161-2 |  Show IntroductionHide Introduction

Genvoya - A New 4-Drug Combination for HIV

   
The Medical Letter on Drugs and Therapeutics • Feb 15, 2016  (Issue 1488)
if Genvoya is discontinued. PREGNANCY — Genvoya is classified as category B (no evidence of risk ...
The FDA has approved Genvoya (Gilead), a fixed-dose combination of the integrase strand transfer inhibitor (INSTI) elvitegravir, the pharmacokinetic enhancer cobicistat, and the nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) emtricitabine and tenofovir alafenamide, for treatment of HIV-1 infection in patients ≥12 years old. This is the first approval for tenofovir alafenamide (TAF), a tenofovir prodrug. Stribild, a fixed-dose combination of elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate (TDF), was approved in 2012.
Med Lett Drugs Ther. 2016 Feb 15;58(1488):19-21 |  Show IntroductionHide Introduction